Shares of Moderna Inc. MRNA,
rose 1.3% in premarket trade on Monday after the company said it plans to launch new development programs using its mRNA technology that will focus on developing vaccines against seasonal flu, HIV and the Nipah virus . This follows the success of its mRNA COVID-19 vaccine, one of two vaccines approved to date by US CEO Moderna also said it plans to extend its respiratory syncytial virus to older adults, and that it plans to test different vaccines. combinations that fight influenza, COVID-19, RSV and human metapneumovirus. “The uniquely challenging year 2020 for society as a whole proved to be an extraordinary proof-of-concept period for Moderna,” CEO Stéphane Bancel said in a press release. As part of the business update, Moderna said it had about $ 5.2 billion in cash on December 31, compared to the $ 1.2 billion in cash it had at the same time a year ago, and expects to have at least $ 11.7 billion in revenue. in 2021 for its COVID-19 vaccine based on purchase agreements. Moderna’s stock is up 489.1% over the past year, while the S&P 500 SPX,
is up 19.7%.